George Tsakonas
Overview
Explore the profile of George Tsakonas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Makrakis D, Rounis K, Tsigkas A, Georgiou A, Galanakis N, Tsakonas G, et al.
PLoS One
. 2023 Nov;
18(11):e0294384.
PMID: 37943779
[This corrects the article DOI: 10.1371/journal.pone.0277708.].
2.
Makrakis D, Rounis K, Tsigkas A, Georgiou A, Galanakis N, Tsakonas G, et al.
PLoS One
. 2023 Feb;
18(2):e0277708.
PMID: 36763597
Obesity and sarcopenia have been reported to affect outcomes in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). We analyzed prospective data from 52 patients...
3.
Kourkoutas D, Tsakonas G, Karamaounas A, Karamaounas N
Case Rep Ophthalmol Med
. 2017 Nov;
2017:5857041.
PMID: 29098100
Chronic central serous chorioretinopathy (CSCR) is a progressive chorioretinopathy with widespread atrophic RPE abnormalities and serous retinal detachments (SRDs) present for 6 months or longer. We report a case of...
4.
Kosmas C, Daladimos T, Athanasopoulos A, Theotikos E, Tsakonas G, Karabelis A, et al.
Future Oncol
. 2010 Dec;
6(11):1803-9.
PMID: 21142665
High-dose chemotherapy intensification and hematopoietic stem cell support remains a valuable treatment option for the rare patient with relapsed Wilms' tumor. We report a 22-year-old adult male with an initially...
5.
Daladimos T, Theotikos E, Athanasopoulos A, Tsakonas G, Karabelis A, Mylonakis N, et al.
Anticancer Drugs
. 2010 Oct;
22(1):111-4.
PMID: 20881835
High-dose chemotherapy and hematopoietic stem cell support remains a valuable treatment option for the rare patient population with relapsed Wilms' tumor. Here we report the case of a 22-year-old male...
6.
Kosmas C, Tsakonas G, Evgenidi K, Gassiamis A, Savva L, Mylonakis N, et al.
Cases J
. 2009 Oct;
2:7612.
PMID: 19830003
Introduction: Malignant peripheral nerve sheath tumors are rare soft tissue sarcomas. They are considered to carry a poor prognosis with current therapeutic approaches. Successful treatment depends on a multimodal approach....
7.
Kosmas C, Tsakonas G, Mylonakis N
Expert Opin Pharmacother
. 2008 Aug;
9(12):2087-98.
PMID: 18671464
Background: CNS metastases constitute the most common brain malignancy in adults and, therefore, represent a challenging issue in cancer treatment. Purpose: To review the role and indication of the various...
8.
Kosmas C, Tsavaris N, Malamos N, Tsakonas G, Gassiamis A, Polyzos A, et al.
Invest New Drugs
. 2007 Mar;
25(5):463-70.
PMID: 17370037
The feasibility of the docetaxel-ifosfamide combination, as well as the definition of maximum tolerated doses (MTD) in a previous phase I study, led us to continue evaluating the regimen in...
9.
Gassiamis A, Tsakonas G, Soukouli G, Mylonakis N, Karabelis A, Kosmas C
Med Oncol
. 2007 Feb;
23(4):455-62.
PMID: 17303903
Multifocal osteosarcoma represents a rare and aggressive type of osteosarcoma in which multiple bone lesions are detected simultaneously in the absence of pulmonary or any other visceral organ involvement. Despite...
10.
Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, et al.
Cancer Chemother Pharmacol
. 2006 Apr;
59(1):51-9.
PMID: 16622691
Purpose: Treatment options in patients with recurrent non-small cell lung cancer (NSCLC) remain limited as a result of poor activity of most agents after failure of platinum-based therapy. In the...